Julia Etchin, Ph.D.
Affiliations: | Yale University, New Haven, CT |
Area:
DNA RepairGoogle:
"Julia Etchin"Mean distance: 6125.08
Parents
Sign in to add mentor| Patrick Sung | grad student | 2010 | Yale | |
| (Roles of BRCA2 and PALB2 in homology-directed repair of chromosomal breaks.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Prutsch N, Jing C, Etchin J, et al. (2019) Abstract 2953: Selective activity of XPO1 inhibitors in TET2-mutant myeloid malignancies Cancer Research. 79: 2953-2953 |
| Akahane K, Li Z, Etchin J, et al. (2017) Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia. British Journal of Haematology |
| Abraham BJ, Hnisz D, Weintraub AS, et al. (2017) Small genomic insertions form enhancers that misregulate oncogenes. Nature Communications. 8: 14385 |
| Etchin J, Berezovskaya A, Conway AS, et al. (2017) Abstract 39: XPO1 inhibitor, KPT-8602, is well tolerated and highly active against AML blasts and LICs Clinical Cancer Research. 23: 39-39 |
| Etchin J, Berezovskaya A, Conway AS, et al. (2016) KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia |
| Townsend EC, Murakami MA, Christodoulou A, et al. (2016) The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 29: 574-86 |
| Etchin J, Montero J, Berezovskaya A, et al. (2015) Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-Initiating cells engrafted into immunosuppressed NSG mice. Leukemia |
| Etchin J, Berezovskaya A, Saur Conway A, et al. (2015) Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML Blood. 126: 326-326 |
| Murakami MA, Christodoulou AN, Christie AL, et al. (2015) Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma Blood. 126: 3252-3252 |
| Etchin J, Le BT, Berezovskaya A, et al. (2015) Abstract 4445: Selective inhibitor of nuclear exporter CRM1/XPO1, Selinexor (KPT-330), exhibits remarkable activity against AML leukemia-initiating cells while sparing normal hematopoietic cells Cancer Research. 75: 4445-4445 |